BridgeBio Pharma, Inc. - 8-K Filing
BridgeBio Pharma reported $194.5 million in first-quarter revenue, including $180.6 million in U.S. Attruby net product revenue, and submitted its first NDA for BBP-418 in LGMD2I/R9. The company also announced a $500 million stock repurchase program and held $940.2 million in cash and equivalents as of March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $BBIO